Literature DB >> 7004214

Chemosuppressive field trials in Thailand. IV. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by mefloquine (WR 142,490, A 4-quinolinemethanol).

E J Pearlman, E B Doberstyn, S Sudsok, W Thiemanun, R S Kennedy, C J Canfield.   

Abstract

The effect of various dosages of mefloquine hydrochloride (WR 142,490) and sulfadoxine-pyrimethamine in the suppression of malaria infections was studied in an area of northeastern Thailand highly endemic for both chloroquine-resistant Plasmodium falciparum and for P. vivax. Both preparations, in all regimens studied, were effective in greatly reducing the incidence of falciparum infections. Mefloquine was more active in preventing vivax parasitemia than sulfadoxine-pyrimethamine; however, this combination remains the commercially available regimen of choice where both parasites occur and P. falciparum is resistant to chloroquine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7004214

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

Review 1.  Prevention of malaria in travellers: a growing problem.

Authors:  J S Keystone; J D MacLean
Journal:  CMAJ       Date:  1989-11-15       Impact factor: 8.262

2.  Single dose kinetic study of the triple combination mefloquine/sulphadoxine/pyrimethamine (Fansimef) in healthy male volunteers.

Authors:  S M Mansor; V Navaratnam; M Mohamad; S Hussein; A Kumar; A Jamaludin; W H Wernsdorfer
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

3.  Approval of Tafenoquine for Malaria Chemoprophylaxis.

Authors:  Jonathan D Berman
Journal:  Am J Trop Med Hyg       Date:  2019-06       Impact factor: 2.345

Review 4.  Prevention of malaria.

Authors:  J S Keystone
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

5.  Malaria prophylaxis with proguanil and sulfisoxazole in children living in a malaria endemic area.

Authors:  L W Pang; N Limsomwong; P Singharaj; C J Canfield
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

Review 6.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

7.  Pharmacokinetics of mefloquine in children aged 6 to 24 months.

Authors:  V Singhasivanon; T Chongsuphajaisiddhi; A Sabcharoen; P Attanath; H K Webster; W H Wernsdorfer; U K Sheth; I Djaja Lika
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Oct-Dec       Impact factor: 2.441

8.  Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sulfadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria.

Authors:  D Botero; M Restrepo; A Montoya
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

Review 9.  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers.

Authors:  A M J Croft; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 10.  Mefloquine for preventing malaria during travel to endemic areas.

Authors:  Maya Tickell-Painter; Nicola Maayan; Rachel Saunders; Cheryl Pace; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.